<DOC>
	<DOCNO>NCT01504321</DOCNO>
	<brief_summary>Polycystic ovary syndrome affect strike 9-18 % Australian reproductive age woman associate number metabolic abnormality . Given strong correlation metabolic abnormality increase sympathetic activity , hypothesise reducing activity use medication ( moxonidine ) help improve metabolic abnormality , therefore improve outcomes polycystic ovary syndrome .</brief_summary>
	<brief_title>Polycystic Ovary Syndrome - Improving Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<criteria>Overweight class I obese premenopausal woman Diagnosis PCOS Rotterdam criteria Any current medication pregnancy desire become pregnant BMI &gt; 35 history type I diabetes , secondary hypertension due PCOS cardiovascular , cerebrovascular , liver thyroid disease severe mental illness .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Polycystic Ovary syndrome</keyword>
	<keyword>PCOS</keyword>
	<keyword>sympathetic nervous system</keyword>
	<keyword>moxonidine</keyword>
</DOC>